Clinical trials: IBD
Ulcerative Colitis
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
The purpose of this study is to determine whether etrasimod (APD334) is a safe and effective treatment for ulcerative colitis after 52 weeks of treatment.
- Trial name
- NCT02536404
- Testing
- Etrasimod
- Where
- 127 sites in United States, Australia and 19 more
- Volunteers
- 118 people
- Sponsor
- Arena Pharmaceuticals
Chronic Diarrhea, Irritable Bowel Syndrome With Diarrhea
Aldafermin (NGM282) for Chronic Diarrhea Due to Bile Acid Malabsorption (BAM)
This single-center, randomized, double-blind, placebo-controlled study is designed to compare effects of aldafermin, (NGM282), 1 mg, and placebo given daily by subcutaneous injection on bowel functions and hepatic synthesis and…
- Conditions
- Chronic Diarrhea, Irritable Bowel Syndrome With Diarrhea, Bile Acid Malabsorption, Bile Acid Diarrhea
- Trial name
- NCT05130047
- Testing
- Aldafermin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Michael Camilleri, MD
Irritable Bowel Syndrome With Diarrhea
Comparing the Efficacy of Nitazoxanide Versus Rifaximin in Adult Patients With Irritable Bowel Syndrome Without Constipation
This study aim to compare the efficacy of nitazoxanide in 2-week course of treatment with rifaximin in treating diarrhea associated with IBS.
- Trial name
- NCT05453916
- Testing
- Nitazoxanide 500Mg Oral Tablet, Rifaximin 550Mg Tab
- Where
- Egypt
- Sponsor
- Sadat City University
Ulcerative Colitis (UC)
A Study for HSK47388 in Participants With Ulcerative Colitis
The purpose of this protocol is to evaluate the efficacy and safety of HSK47388 as therapy in participants with moderately to severely active ulcerative colitis .
- Trial name
- NCT07335055
- Testing
- HSK47388
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
Pediatric Inflammatory Bowel Diseases, Pediatric Crohns Disease
Exercise Training in Youth With Inflammatory Bowel Disease
Children and adolescents with inflammatory bowel disease (IBD) suffer from many extra-intestinal side effects, including impaired muscle strength, low aerobic fitness, low bone density, and chronic inflammation.
- Conditions
- Pediatric Inflammatory Bowel Diseases, Pediatric Crohns Disease, Pediatric Ulcerative Colitis
- Trial name
- NCT05591976
- Testing
- Exercise training program
- Where
- Canada
- Volunteers
- 11 people
- Sponsor
- McMaster University
Crohn's Disease
Development of Niv Score of Capsule Endoscopy in Patients With Crohn's (CECDAIic)
Hypothesis This study is designed as an integral part of the development of a new CE score for Crohn's disease. The SB (small bowel) CD (Crohn's Disease)Niv score (CECDAI) is an established and validated CD score for SB…
- Trial name
- NCT01793376
- Volunteers
- 30 people
- Sponsor
- Medtronic - MITG
Inflammatory Bowel Diseases
Gallstones and Risk of Inflammatory Bowel Disease
The purpose of this study was to evaluate the association between gallstone disease and the risk of inflammatory bowel disease.
- Trial name
- NCT05882006
- Testing
- gallstones
- Where
- 4 sites in China
- Volunteers
- 5,035 people
- Sponsor
- Hepatopancreatobiliary Surgery Institute of Gansu Province
Crohns Disease
A Randomized, Double-Blind, Placebo-Controlled Dose-Escalation Study to Determine the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Crohn's Disease
To assess the safety and efficacy of intravenous (IV) PDA001 infused every two weeks for up to 5 total infusions in subjects with Crohn's disease who are refractory to one or more standard Crohn's disease therapies.
- Trial name
- NCT01769755
- Testing
- PDA001
- Where
- 12 sites in United States
- Volunteers
- 14 people
- Sponsor
- Celularity Incorporated
Ulcerative Colitis, Crohn's Disease
Vedolizumab Subcutaneous (SC) Versus Intravenous (IV) in Ulcerative Colitis or Crohn's Disease
The purpose of this study is to assess the bioavailability and pharmacokinetics (PK) of multiple doses of vedolizumab subcutaneous (SC) compared to vedolizumab intravenous (IV).
- Trial name
- NCT02913508
- Testing
- Vedolizumab intravenous injection, Vedolizumab subcutaneous injection
- Sponsor
- Takeda
Ulcerative Colitis (UC), Crohn Disease (CD)
Fluorescence Imaging of Risankizumab-800CW in Inflammatory Bowel Disease
Crohn\'s Disease (CD) and Ulcerative Colitis (UC) are chronic inflammatory bowel diseases (IBD). Risankizumab is a human monoclonal antibody against IL23 p19, part of a pro-inflammatory cytokine that mediates the inflammatory…
- Trial name
- NAVIGATE (NCT06606808)
- Testing
- Risankizumab-800CW 4.5 mg, Risankizumab-800CW 15 mg, Risankizumab-800CW 25 mg
- Where
- Netherlands
- Volunteers
- 18 people
- Sponsor
- University Medical Center Groningen
Stoma - Ileostomy, High Output Stoma
Study of Treatment With Intensified Omeprazole Treatment to Prevent High Output Stoma 1
The goal of this clinical trial is to evaluate if intensified omeprazole therapy can reduce high-output stoma (HOS) in adults undergoing ileostomy formation surgery.
- Conditions
- Stoma - Ileostomy, High Output Stoma, Colon Cancer, IBD (Inflammatory Bowel Disease)
- Trial name
- STOP-HOS-1 (NCT06917963)
- Testing
- Intensified intravenous omeprazole therapy (loading dose 80 mg IV, then 40 mg IV twice daily at 6:00 AM and 6:00 PM), Standard intravenous omeprazole therapy (40 mg IV once daily at 6:00 AM).
- Where
- 2 sites in Poland
- Volunteers
- 80 people
- Sponsor
- Medical University of Gdansk
Ulcerative Colitis
Hyperbaric Oxygen Therapy for Ulcerative Colitis (HBOT-UC)
Chronic intestinal hypoxia and accompanying mucosal inflammation is a hallmark of ulcerative colitis (UC). Hyperbaric oxygen therapy (HBOT) involves breathing 100% oxygen under increased atmospheric pressure to increase tissue…
- Trial name
- HBOT-UC (NCT05987852)
- Testing
- Hyperbaric Oxygen Therapy
- Where
- 13 sites in United States
- Volunteers
- 126 people
- Sponsor
- Northwestern University
Chronic Pain, Chronic Pain Syndrome
Outcomes Mandate National Integration With Cannabis as Medicine
This will be a multistate, multicenter clinical study to determine the efficacy and safety of medical cannabis for a wide variety of chronic medical conditions.
- Conditions
- Chronic Pain, Chronic Pain Syndrome, Chronic Pain Due to Injury, Chronic Pain Due to Trauma
- Trial name
- OMNI-Can (NCT03944447)
- Testing
- Cannabis, Medical, RYAH-Medtech Inhaler
- Where
- 17 sites in United States
- Volunteers
- 200,000 people, healthy volunteers welcome
- Sponsor
- OMNI Medical Services, LLC
Crohn Disease (CD), Colitis Ulcerative
Characterization of Colorectal Dysplasic Lesions and Stratification of Their Evolving Risk in Inflammatory Bowel Disease Patients: a Prospective, Observational and Multicenter Study
Inflammatory Bowel Disease (IBD) patients have an increased risk of ColoRectal Cancer (CRC). The cumulative risk of CRC development is estimated at 1% after 10 years of disease progression, 2% after 20 years, and 5% after more…
- Trial name
- IB DYSPLASIA (NCT07719426)
- Volunteers
- 800 people
- Sponsor
- Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
Ulcerative Colitis
Study to Evaluate the Clinical Activity and Safety of Oral NX-13 in Moderate to Severe Ulcerative Colitis
Phase 2 induction study with a long-term extension (LTE) period in participants with moderate to severe ulcerative colitis (UC).
- Trial name
- NCT05785715
- Testing
- NX-13 250mg, NX-13 750mg
- Where
- 35 sites in United States, Belgium and 2 more
- Volunteers
- 81 people
- Sponsor
- AbbVie
Inflammatory Bowel Disease (Crohn's Disease; Ulcerative Colitis), Adherence, Patient
Treatment Adherence Among Patients With Inflammatory Bowel Disease Receiving Anti-TNF Therapy
Inflammatory bowel disease (IBD) is a chronic condition characterized by periods of remission and relapse, requiring long-term treatment adherence to maintain disease control and prevent complications.
- Conditions
- Inflammatory Bowel Disease (Crohn's Disease; Ulcerative Colitis), Adherence, Patient, Structured Education
- Trial name
- NCT07652840
- Testing
- Health Belief Model-Based Structured Patient Education, Standard Patient Education
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 140 people
- Sponsor
- Izmir Katip Celebi University
IBD - Inflammatory Bowel Disease, RA - Rheumatoid Arthritis
A Pharmacokinetic-pharmacodynamic Modeling and Simulation Study of Subcutaneous Infliximab in Patients With Inflammatory Bowel Disease
A subcutaneous formulation of infliximab CT-P13 (Remsima, Celltrion) has been approved for clinical use in inflammatory bowel disease (IBD) and rheumatoid arthritis (RA) after demonstration of pharmacokinetic (PK) non-inferiority…
- Trial name
- NCT07120152
- Testing
- Subcutaneous infliximab CT-P13 Remsima®SC
- Volunteers
- 439 people, healthy volunteers welcome
- Sponsor
- Erwin Dreesen
Crohn's Disease, Ulcerative Colitis
Pilot Study of an Online Therapeutic Education Program for Patients With Inflammatory Bowel Disease
EDUMICILOR is a monocentric prospective pilot study for patients with inflammatory bowel disease (IBD). During the study, patients will participate in an online therapeutic education program.
- Trial name
- EDUMICILOR (NCT03648398)
- Testing
- EDUMICILOR
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Central Hospital, Nancy, France
Irritable Bowel Syndrome
Effects of Standardized Boswellia Carterii Extract on Irritable Bowel Syndrome Patients
Irritable bowel syndrome (IBS) is a common condition that affects the stomach and intestines. It can cause abdominal pain, bloating, diarrhea, constipation, and changes in bowel habits, which may reduce a person's quality of…
- Trial name
- BC-IBS (NCT07576634)
- Testing
- Boswellia carterii Extract, Educationntal program for IBS patie
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Mansoura University
Irritable Bowel Syndrome, Post Infective Bowel Dysfunction
Saccharomyces Cerevisiae CNCM I-3856 Treatment in Irritable Bowel Syndrome With Diarrhea (IBS-D) and Post Infective Bowel Dysfunction
Irritable Bowel Syndrome (IBS) is a common condition characterised by abdominal pain or discomfort and altered bowel habit affecting up to 10% of the population.
- Trial name
- NCT00977587
- Testing
- Saccharomyces Cerevisiae CNCM I-3856
- Where
- United Kingdom
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Nottingham